Journal article
Immunogenicity of hiv-1-based virus-like particles with increased incorporation and stability of membrane-bound env
CA Gonelli, HAD King, C Mackenzie, S Sonza, RJ Center, DFJ Purcell
Vaccines | MDPI | Published : 2021
Abstract
An optimal prophylactic vaccine to prevent human immunodeficiency virus (HIV-1) transmission should elicit protective antibody responses against the HIV-1 envelope glycoprotein (Env). Replication-incompetent HIV-1 virus-like particles (VLPs) offer the opportunity to present virion-associated Env with a native-like structure during vaccination that closely resembles that encountered on infectious virus. Here, we optimized the incorporation of Env into previously designed mature-form VLPs (mVLPs) and assessed their immunogenicity in mice. The incorporation of Env into mVLPs was increased by replacing the Env transmembrane and cytoplasmic tail domains with those of influenza haemagglutinin (HA-..
View full abstractRelated Projects (2)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This research was funded by grants to D.F.J.P. by Horizon 2020 grant 1115828 and program grant 1052979 from the National Health and Medical Research Council (NHMRC) of Australia, and a project grant from Australian Centre for HIV and Hepatitis Virology (ACH2).